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Abstract
Background:  New, third-generation aromatase inhibitors (AIs) have proven comparable or
superior to the anti-estrogen tamoxifen for treatment of estrogen receptor (ER) and/or
progesterone receptor (PR) positive breast cancer. AIs suppress total body and intratumoral
estrogen levels. It is unclear whether in situ carcinoma cell aromatization is the primary source of
estrogen production for tumor growth and whether the aromatase expression is predictive of
response to endocrine therapy. Due to methodological difficulties in the determination of the
aromatase protein, COX-2, an enzyme involved in the synthesis of aromatase, has been suggested
as a surrogate marker for aromatase expression.
Methods: Primary tumor material was retrospectively collected from 88 patients who participated
in a randomized clinical trial comparing the AI letrozole to the anti-estrogen tamoxifen for first-line
treatment of advanced breast cancer. Semi-quantitative immunohistochemical (IHC) analysis was
performed for ER, PR, COX-2 and aromatase using Tissue Microarrays (TMAs). Aromatase was
also analyzed using whole sections (WS). Kappa analysis was applied to compare association of
protein expression levels. Univariate Wilcoxon analysis and the Cox-analysis were performed to
evaluate time to progression (TTP) in relation to marker expression.
Results: Aromatase expression was associated with ER, but not with PR or COX-2 expression in
carcinoma cells. Measurements of aromatase in WS were not comparable to results from TMAs.
Expression of COX-2 and aromatase did not predict response to endocrine therapy. Aromatase
in combination with high PR expression may select letrozole treated patients with a longer TTP.
Conclusion: TMAs are not suitable for IHC analysis of in situ aromatase expression and we did
not find COX-2 expression in carcinoma cells to be a surrogate marker for aromatase. In situ
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aromatase expression in tumor cells is associated with ER expression and may thus point towards
good prognosis. Aromatase expression in cancer cells is not predictive of response to endocrine
therapy, indicating that in situ estrogen synthesis may not be the major source of intratumoral
estrogen. However, aromatase expression in combination with high PR expression may select
letrozole treated patients with longer TTP.
Trial registration: Sub-study of trial P025 for advanced breast cancer.
Background
Treatment with the non-steroidal antiestrogen (AE)
tamoxifen has been the first-line endocrine treatment of
choice for breast cancer patients for more than 30 years.
However, the third-generation aromatase inhibitors (AIs)
anastrozole, letrozole and exemestane have in large rand-
omized trials shown to be comparable or superior to
tamoxifen as treatment for postmenopausal women with
hormone receptor (HR) positive metastatic breast cancer
[1-6]. The objective response rates ranged from 21% to
33% with clinical benefit rate varying between 49% and
59% [1,2,4], necessitating improvements in treatments
and development of response predictors to the different
options.
Expression of the estrogen receptor (ER) is a prerequisite
for estrogen dependent tumor growth and ER positivity in
the primary tumor has been used as a selection criterion
for endocrine therapy since 1975 [7]. Furthermore, ER is
also well known to be an important prognostic factor,
indicating good prognosis [8]. The progesterone receptor
(PR) is an estrogen-inducible protein and improved
response rates have been seen in tumors, which besides
ER, also express PR [9-11], with increasing ER and PR
scores being associated with better response to tamoxifen
in ER positive metastatic breast cancer [12]. Today, most
laboratories perform immunohistochemical (IHC) deter-
mination of both ER and PR and a good correlation
between the quantitative level determined with the classi-
cal ligand-binding assays and the immunohistochemical
scores have been found for both ER and PR [12].
The third-generation AIs anastrozole, letrozole and
exemestane suppress total-body aromatization by 98%,
more than 99% and 98%, respectively [13,14], demon-
strating the superior suppressive potency of these drugs
compared to the previous first- and second-generation
compounds [15]. Furthermore in studies with direct
measurements of estrogen levels in tumor tissue, AI treat-
ment resulted in nearly complete suppression of intratu-
moral estrogen levels [16-20]. The intratumoral estrogen
level may arise from local estrogen production in carci-
noma cells or surrounding cells as well as from the uptake
of peripherally generated estrogens, and so it has been
debated whether the in situ estrogen production in the car-
cinoma cells is the major contributor to estrogen-stimu-
lated tumor growth and thus may be a predictor of
response to treatment with AIs [14,21-24]. Biochemically
determined intratumoral aromatase enzyme activity has
shown correlation with response to treatment with AI
[25], and classic estrogen-dependent genes and prolifera-
tion markers changed in most tumors during treatment
irrespective of response [26], supporting the hypothesis
that in situ estrogen synthesis may be used as a predictive
marker for response to treatment with aromatase inhibi-
tor. Attempts have been made to measure the aromatase
protein in the tumor tissue as an alternative to the bio-
chemical assay. The aromatase protein has been detected
in both fibroblasts, adipose cells, benign duct cells and
invasive cancer cells and the results have been contradic-
tory with respect to which cell types in the breast express
the aromatase protein [27-33]. A promising new aro-
matase antibody (#677) has shown immunoreactivity in
carcinoma cells, stromal cells or fibroblasts, adipocytes,
normal epithelium, and inflammatory cells [31]. The
multiplicative SIP score for carcinoma cells ("Proportion
of aromatase immunopositivity" multiplied with "Rela-
tive intensity of aromatase immunoreactivity") was posi-
tively correlated with the aromatase enzyme activity
measured by the biochemical tritiated-water release assay
[32], indicating that aromatase expression in the carci-
noma cells may be a predictive marker for response to AI
treatment. Furthermore, since PR expression is induced by
estrogen binding to ER, it may be hypothesised that high
PR expression in combination with aromatase expression
in primary tumor tissue identifies patients with superior
benefit from AI treatment.
Due to the difficulties regarding determination of the aro-
matase protein expression and activity, cyclooxygenase-2
(COX-2) has been proposed as a surrogate marker for aro-
matase expression [34]. COX-2 is an isoform of the pros-
taglandin endoperoxidase synthetase that catalyzes key
steps in the metabolism of arachidonic acid to prostaglan-
din E2 (PGE2), thereby regulating the synthesis of aro-
matase [35-37]: Expression of aromatase is controlled by
unique promoters that lie upstream of tissue-specific
exons. These first exons are alternatively spliced onto a
common site upstream of the translation initiation codon
in exon II. The aromatase mRNAs have unique 5'-untrans-
lated regions, but the sequences encoding the aromatase
enzyme are identical. In tumor tissue aromatase is up reg-BMC Cancer 2009, 9:185 http://www.biomedcentral.com/1471-2407/9/185
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ulated by switching from the weak promoter I.4 to the
strong promoters IIa and I.3. Switching from promoter I.4
to IIa and I.3 is likely to be mediated by the induction of
COX-2 [38], which is expressed in a variety of cancers
including invasive breast cancer [39-41].
The aim of this study was to explore whether the expres-
sion level of the aromatase protein in carcinoma cells
alone or in combination with PR expression in the pri-
mary tumor may be predictive for response to treatment
with the AI letrozole or the AE tamoxifen in the advanced
breast cancer setting. The predictive utility of COX-2 for
endocrine treatment as well as a surrogate marker for aro-
matase expression was also investigated. We have pre-
pared tissue micoarrays (TMAs) and performed IHC
analyses of ER, PR, COX-2 and aromatase in primary
tumor tissue from 88 of the 907 patients who participated
in the multicenter randomized phase III P025 trial which
compared first-line tamoxifen or letrozole treatment in
postmenopausal women with locally advanced or meta-
static breast cancer [2,3]. A semi-quantitative IHC score
has been determined for each of the four parameters. For
aromatase expression, an evaluation of IHC staining in
whole sections versus staining in TMAs was performed as
previously described for ER, PR and COX-2 [42].
Methods
This study was derived from the P025 study, an interna-
tional, multicenter, double-blind, randomized, two-arm,
phase III clinical trial comparing letrozole with tamoxifen
as first-line treatment for postmenopausal women with
advanced breast cancer [2]. The P025 study was con-
ducted in accordance with the ethical principles that orig-
inated in the Helsinki II declaration and the appropriate
local ethics review boards have approved the study,
number by local ethical review board: 01025-KF12-138-
99.
For this current sub-study it was possible to collect pri-
mary tumor material from 68 Danish patients and from
20 patients from the rest of Europe. Thus, altogether, par-
affin blocks containing primary tumor material from 88
patients were collected. Sixty-five tumors were classified as
invasive ductal and 12 as invasive lobular carcinoma.
Three tumor samples were classified as neither lobular nor
ductal and eight samples were not suitable for classifica-
tion. Three of the 88 patients were originally allocated to
a combination treatment of letrozole and tamoxifen. This
combination therapy arm was stopped in the original
P025 study and the patients were excluded from the inten-
tion to treat analysis, thus 85 patients are included in the
present study, unless for comparison of aromatase expres-
sion in WS and TMAs where tissue from all 88 tumors
were included. The end-point Time To Progression (TTP),
is defined as described by Mouridsen et al. 2001 [2]. All
patient data used in this study were provided by Novartis
Phama AG, (Basel Switzerland) to the Danish Breast Can-
cer Cooperative Group (DBCG), following agreement
with the departments who treated the patients.
Immunohistochemical staining of ER, PR and COX-2
Sections, 3 μm, were dewaxed in coconut oil and rehy-
drated in a graded series of ethanol. Slides were preheated
for 10 min. and boiled for 15 min. in microwave oven at
600 W in TEG buffer (pH = 9, Bie & Berntsen, Denmark)
for antigen retrieval and rinsed in tap water. All immunos-
tainings were performed at room temperature using the
automated immunostainer Tech-mate 500 (Dako, Den-
mark), according to the following protocol: Slides were
washed in TBS + 0.1% BRIJ-35 detergent (AX-LAB, Den-
mark) and incubated with primary antibody diluted in
TBS + 0.1% BRIJ-35 + 1% BSA (Bovine Serum Albumin) +
15 nM sodiumazide for 60 min. After washing, endog-
enous peroxidase activity was blocked using 3% H2O2 in
TBS + 0.1% BRIJ-35. The ChemMate EnVision+ Detection
Kit (Peroxidase/Dab, Rabbit/Mouse, K5007, Dako, Den-
mark) was used as detection system for the primary anti-
bodies. After washing, slides were counterstained with
haematoxylin and dehydrated in graded series of ethanol,
and finally mounted with Pertex (Histolab, Denmark).
The following primary antibodies, all monoclonal mouse
subtype IgG1, were used: ER, clone ER1D5, 1:200 (Immu-
notech); PR, clone 16, 1:200 (Novocastra); COX-2, no
6111104, 1:150 (Cayman Chemicals). The specificity of
the immunoreactions was verified by substitution of the
primary antibody with the corresponding concentration
of mouse IgG1, X 0931 (Dako, Denmark). In addition,
positive control slides with breast tumor tissue or other
tissue known to stain positive were included in every run.
All stainings of the individual antigens were performed in
a single run in order to minimize interserial staining vari-
ation.
Immunohistochemical staining of Aromatase
All aromatase staining as well as evaluation of the staining
was conducted by the author Hironobu Sasano. Sections,
3 μm, were stained and analyzed as described in Sasano et
al. 2005 [32]. In brief: tissue sections were immunos-
tained by a biotin-streptavidin method using a Histofine
kit (Nichirei Co. Ltd., Tokyo, Japan). The antigen-anti-
body complex was subsequently visualized with 3.3'-
diaminobenzidine solution (DAB) and counterstained
with hematoxylin. Evaluation of aromatase IHC was per-
formed by assessing the approximate percentage of carci-
noma cell staining (proportion score) and classifying the
proportion score values as the following: 0 = <1%, 1 = 1–
25%, 2 = 26–50%, 3 = 51–75% and 4 = 76–100% immu-
nopositive cells. The relative intensity of aromatase
immune-positive cells was classified as follows: 0 = no
immunoreactivity, 1 = weak, 2 = moderate and 3 = intenseBMC Cancer 2009, 9:185 http://www.biomedcentral.com/1471-2407/9/185
Page 4 of 12
(page number not for citation purposes)
immunoreactivity. The SIP score is the proportion score
multiplied with the relative intensity score. The evaluation
of the aromatase immunoreactivity was performed with-
out the knowledge of response to treatment.
Preparation of tissue microarrays
TMA blocks were constructed using the TMA-builder from
Histopathology Ltd. (AH-diagnostics, Denmark). Targets
for arraying (areas with representative invasive tumor)
were identified by marking the corresponding areas on
haematoxylin-eosin stained sections from each paraffin
block. Two tissue cores with a diameter of 2 mm were
transferred from each donor block to the recipient TMA
block. Kidney tissue was placed in the first core of the
upper left and right corner of the TMA block to ensure cor-
rect orientation when examining the slides. All analyses
were performed on TMAs [42], whereas analysis for aro-
matase was performed on whole sections (WS) as well.
Evaluation of ER, PR and COX-2 immunohistochemical 
staining
All specimens were evaluated without knowledge of the
clinical data. TMA slides were evaluated by light micros-
copy and the authors Katrine L. Henriksen scored all the
samples and Birgitte B. Rasmussen has been consulted in
cases of doubt. Only invasive tumor components were
considered when assessing the staining. Semi-quantitative
determination of ER and PR was performed according to
the method described by Allred et al. [43]. This method
was also used for semi-quantitative determination of the
non-nuclear cytoplasmatic marker COX-2. In brief: The
proportion of positive stained cells was judged as 0 = no
cells stained, 1 = between 0 and 1% stained positive, 2 =
between 1 and 10% stained positive, 3 = between 10 and
33% stained positive, 4 = between 33 and 66% stained
positive, 5 = between 66 and 100% stained positive. In
addition to the proportion score, an intensity score was
made based on the average intensity of staining, 0 = neg-
ative, 1 = weak, 2 = intermediate and 3 = strong. The inten-
sity score and the proportion score was added to obtain
the total score referred to as the Allred score, which is 0 or
between 2 and 8, 0 and 2 were interpreted as negative.
Only nuclear staining was judged when scoring ER and
PR, whereas cytoplasmatic staining was scored for COX-2.
Evaluation of Aromatase immunohistochemical staining
Evaluation of aromatase staining in WS was done using
the SIP score as described in Sasano et al. 2005 [32]. As
described above, when preparing TMAs only areas con-
taining primary tumor was used, thus instead of determin-
ing a SIP score the determination of "relative intensity of
aromatase immunoreactivity" in carcinoma cells was
scored for TMAs and not the "proportion of aromatase
immunopositivity". Consequently no SIP score was
obtained for the TMA sections.
Statistical Analysis
Chi-square test was used to evaluate if the patients in the
present study represent the entire study population of
patients. The Kappa score was used to evaluate the agree-
ment of aromatase immunointensity of carcinoma cells
on whole sections (WS) versus TMAs, and for this analysis
results from all 88 collected tumor samples were included.
The Systematic difference between the scores on TMA and
whole sections was analysed with Wilcoxon's Signed Rank
Sum test on the difference (TMA-WS) and the Concord-
ance is determined as the number of samples with no dif-
ference in scoring value in relation to the number of
samples with a different scoring value and P-values for
evaluation of WS versus TMA are given (Table 1). The
association of aromatase expression with COX-2, as well
as the agreement between expression of aromatase with
ER and PR was done by calculating the Kappa score and P-
values are given. Time to progression (TTP) was the pri-
mary endpoint in the P025 trial and was defined as the
interval between the date of randomisation and the earli-
est date of disease progression. Kaplan-Meier plots were
used to illustrate univariate survival and differences in TTP
between subgroups were evaluated by the Wilcoxons rank
sum test. A multivariate Cox proportional hazards model
was used to investigate the effect of treatment and each of
the parameters aromatase, COX-2 and PR, expressed as
semi-quantitative IHC results. Interaction between treat-
ment and aromatase expression was further investigated
by subgroup analysis within each treatment group. When
analysis of grouped scoring values was applied, scoring
values were grouped as follows: For ER, PR and COX-2-
expression "high" is defined as Allred score 7 or 8, "low"
as Allred score 3 to 6 and "negative" as 0 or 2. For Aro-
matase, "high" is defined as SIP score 9 and 12, "low" as
SIP score 1,2,3,4,6 or 8, and "negative" as SIP score 0 (See
Table 2). In all tests, a P-value < 0.05 was used as level of
significance.
Table 1: Comparison of carcinoma cell aromatase immunointensity in TMA and WS
TMA versus WS n = 69 Concordance Test for no difference Kappa score
26% (p < 0.002) 0.0048 (-0.080–0.17)
(P = 0.41)BMC Cancer 2009, 9:185 http://www.biomedcentral.com/1471-2407/9/185
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Table 2: Semi-quantitative IHC results: ER, PR, COX-2 and Aromatase
Let n = 46 Tam n = 39 Total (n = 85)
ER level (Allred score)
negative ≤ 23 2 5
Low 30 0 0
41 1 2
52 1 3
66 3 9
High 71 0 8 1 8
82 1 1 9 4 0
N.A. (not assessable) 35 8
Total positive 40 32 72
PR level (Allred score)
negative ≤ 29 9 1 8
Low 33 1 4
45 3 8
54 5 9
61 6 7
High 76 0 6
81 4 1 2 2 6
N.A. (not assessable) 43 7
Total positive 33 27 60
COX-2 level (Allred score)
negative ≤ 21 3 1 1 2 4
Low 30 2 2
45 4 9
51 0 2 1 2
67 6 1 3
High 75 7 1 2
81 0 1BMC Cancer 2009, 9:185 http://www.biomedcentral.com/1471-2407/9/185
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Results
Patient data
The P025 trial recruited 907 patients and archived paraf-
fin embedded tissue was collected from the primary
tumor of 88 patients, of which 85 (9.4%) could be
included in the clinical analyses [2]. As in the original
study, the patients (85) are well balanced according to
treatment allocation, 46 (54%) to letrozole and 39 (46%)
to tamoxifen, age at randomization and Karnofsky Per-
formance Score. However, the assessable patients differed
from the total trial cohort with respect to having a signifi-
cantly more advanced stage of disease at study entry and
with respect to a larger proportion having received prior
adjuvant treatment with tamoxifen (P < 0.01). In our sub-
group of 85 patients the median TTP for letrozole treat-
ment was 9.5 months (90% range: 0.33–39) and 9.5
months (90% range: 2.6–46) for tamoxifen. More
detailed patient data are given in Henriksen et al. 2009
[44].
Evaluation of aromatase staining in whole sections versus 
tissue microarrays
All of the collected 88 tumor samples were used for com-
parison, but for 19 of the samples either the WS or TMA
results were missing due to technical reasons, thus 69
measurements were compared (Table 1). For 18 of the 69
tumors the same aromatase carcinoma cell intensity score
was obtained from WS and TMA, resulting in a concord-
ance of 26%. In 13 cases, the result obtained on TMA was
higher than the result from WS, and for 38 of the samples
WS scores were higher than TMA. A test for symmetry dis-
closed a systematic difference (P = 0.0013) and a signifi-
cant difference was confirmed by the Signed Rank test (P
< 0.002). We have further compared the expression level
of carcinoma cell staining intensity by Kappa statistics and
found that results obtained from WS and TMAs were not
significantly associated (P = 0.41). Figure 1 shows exam-
ples of aromatase staining of breast tumor tissue from WS
and TMAs. High aromatase expression in carcinoma cells
is shown in Figure 1A and 1B, whereas 1C and 1D show
low aromatase expression in carcinoma cells. Figure 1E
and 1F illustrate a discordant staining result with high
score in WS and low score in TMA.
Scoring results of IHC staining of ER, PR, COX-2 and 
aromatase
ER, PR and COX-2 levels were scored by the Allred score
on TMAs, as we have previously shown concordance
between scores on TMAs and WS [42], whereas aromatase
was analyzed on WS and evaluated by the SIP score. The
semi-quantitative scoring results of ER, PR, COX-2 and
aromatase are shown in Table 2. For all four markers the
N.A. (not assessable) 57 1 2
Total positive 28 21 49
Aromatase level (Carcinoma cell SIP score)
negative 01 0 5 1 5
Low 13 3 6
29 3 1 2
32 3 5
45 9 1 4
68 5 1 3
80 2 2
High 92 3 5
12 2 1 3
N.A. (not assessable) 55 1 0
Total positive 30 30 60
Table 2: Semi-quantitative IHC results: ER, PR, COX-2 and Aromatase (Continued)BMC Cancer 2009, 9:185 http://www.biomedcentral.com/1471-2407/9/185
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Representative pictures of immunohistochemical aromatase staining of primary breast tumor tissue with the antibody #677 Figure 1
Representative pictures of immunohistochemical aromatase staining of primary breast tumor tissue with the 
antibody #677. (A) WS with high level of aromatase expression. (B) TMA with high level of aromatase expression. (C) WS 
with low level of aromatase expression. (D) TMA with low level of aromatase expression. (E) WS from a tumor showing het-
erogeneity in carcinoma cell staining intensity scored as high expression (score value 9). (F) A TMA illustrating discordant low 
intensity score (score value 1).BMC Cancer 2009, 9:185 http://www.biomedcentral.com/1471-2407/9/185
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distribution of semi-quantitative scoring results were well
balanced. The majority of tumors had a high Allred score
for ER and PR. Only 6% of the tumors are scored negative
for ER, 16% are scored low and 68% are scored high. The
PR is more evenly distributed on the Allred scale, 21% of
the tumors are scored negative, 33% low and 38% of the
patients have a high expression of PR. None of the tumors
were negative for both ER and PR. High cytoplasmic stain-
ing of COX-2 was observed in 15% of the samples, 42 %
showed low COX-2 expression, and 28% were negative.
The majority of tumours stained positive for aromatase,
61% with low expression and 9% were scored as high,
whereas 18% was scored negative for the aromatase pro-
tein. For all markers technical problems impaired the
scoring of between 7 and 12 of the tumor samples making
them "not assessable" (N.A.).
Association between aromatase expression and COX-2, 
ER and PR
To examine the association between tumor cell aromatase
expression and the supposed surrogate marker COX-2, we
performed Kappa statistics. Furthermore, the association
between aromatase and ER as well as the estrogen-regu-
lated protein PR was evaluated. Aromatase expression was
not found to be associated with the expression of either
COX-2 (P = 0.46) or PR (P = 0.83). However, a strong
trend towards an association between tumor cell expres-
sion of aromatase and ER was found, (P = 0.057).
COX-2 and aromatase expression for selection of 
treatment with either letrozole or tamoxifen
To evaluate whether our IHC analyses of either COX-2 or
aromatase expression could be used to discriminate
between TTP for patients treated with tamoxifen or letro-
zole, we compared TTP for all patients separated in sub-
groups of negative, low or high expression of the two
markers. For each marker TTP was compared by uni-vari-
ate Wilcoxon-test and Kaplan-Meier plots as shown in Fig-
ure 2. Neither COX-2 nor aromatase expression was
associated with superiority of either letrozole or
tamoxifen in terms of TTP, P = 0.99 and P = 0.72 respec-
tively. In agreement, a Cox analysis of COX-2 and aro-
matase expression level in relation to total endocrine
treatment (letrozole- and tamoxifen-treated patients
together) disclosed no difference in TTP between patients
with negative, low or high marker expression, P = 0.95
and P = 0.94 for COX-2 and aromatase, respectively.
Aromatase and PR expression for selection of treatment 
with either letrozole or tamoxifen
As described above, we have compared the expression
level of aromatase with ER and PR by Kappa statistics, and
whereas the PR expression level was independent of aro-
matase expression, a strong trend towards association of
aromatase and ER was found (P = 0.057). Thus, aromatase
positivity combined with PR expression might add infor-
mation regarding TTP for patients treated with tamoxifen
Time to progression (TTP) according to high, low and negative expression of COX-2 and Aromatase in primary tumor tissue  for patients treated with either letrozole (black) or tamoxifen (grey) Figure 2
Time to progression (TTP) according to high, low and negative expression of COX-2 and Aromatase in pri-
mary tumor tissue for patients treated with either letrozole (black) or tamoxifen (grey). (A) TTP according to 
COX-2 expression: Letrozole treatment, COX-2 high, n = 6; COX-2 low, n = 22; COX-2 negative, n = 13. Tamoxifen treat-
ment, COX-2 high, n = 7; COX-2 low, n = 14; COX-2 negative, n = 11. (B) TTP according to Aromatase expression: Letro-
zole treatment, Aromatase high, n = 4; Aromatase low, n = 27; Aromatase negative, n = 10. Tamoxifen treatment, Aromatase 
high, n = 4; Aromatase low, n = 25; Aromatase negative, n = 4.
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or letrozole. When looking at all patients (letrozole- and
tamoxifen-treated patients together), Cox analysis dis-
closed a significant difference between TTP for patients
with aromatase positive tumors with negative, low and
high PR content (P = 0.023), with high PR associated with
long TTP. A further subgroup analysis of tamoxifen- and
letrozole-treated patients showed a strong trend towards a
different TTP for patients treated with letrozole (P  =
0.059), but not for tamoxifen treated patients (P = 0.14),
Figure 3A and 3B.
Discussion
In this small retrospective sub-study of the P025 trial we
have analyzed aromatase, COX-2, ER and PR expression
by semi-quantitative IHC in primary tumor material from
9.4% of the patients included in the original study. The
patients in our study were rather equally distributed
regarding allocation to letrozole or tamoxifen. Our aim
was to investigate whether aromatase- or COX-2 expres-
sion could be used as single markers for treatment, or if
aromatase in combination with PR expression, could be
used to select patients for treatment with either tamoxifen
or letrozole. Furthermore, the utility of COX-2 as a surro-
gate IHC marker for aromatase as well as the feasibility of
analysing aromatase expression by TMAs was evaluated.
In spite of the many resources and efforts applied to
understand the basis of development, progression and
prediction of response to treatment of breast cancer, only
three predictive markers (ER, PR and HER-2) are recom-
mended for routine IHC testing in breast cancer. Two of
these, ER and PR, are predictive for response to endocrine
treatment [45]. Since aromatase is the key enzyme in the
estrogen synthesis and is expressed in both breast carci-
noma cells, surrounding stromal cells as well as endothe-
lial and benign breast cells [27,34], many attempts have
been made to evaluate the importance of aromatase
expression in the different cell types in the breast for local
estrogen production and for utility as prognostic and pre-
dictive marker. The obtained results have been contradic-
tory [26-29,33,46,47]. However, recent data have shown
that the aromatase antibody #677 is very specific for IHC
detection of the aromatase protein [31,32]. Although it
has been assumed that the estrogen production in the sur-
rounding stromal cells contributes significantly to the
estrogen level within the carcinoma cells, it was found
that only the IHC staining of aromatase in the carcinoma
cells was correlated to the aromatase enzyme activity in
the breast tissue [32]. Therefore, in this study we have
firstly evaluated whether carcinoma cell aromatase detec-
tion with the #677 antibody gave comparable results in
TMA and WS. The observed systematic difference and
higher aromatase carcinoma cell staining intensity in WS
compared to TMA can be explained by the marked heter-
ogeneity of aromatase expression in the tumor tissue as
illustrated in Figure 1E. Thus, the present study can not
support TMA analysis of aromatase and accordingly, we
have used the aromatase results obtained from WS when
Time to progression (TTP) according to high, low and negative PR expression in aromatase positive primary tumours from  patients treated with letrozole or tamoxifen Figure 3
Time to progression (TTP) according to high, low and negative PR expression in aromatase positive primary 
tumours from patients treated with letrozole or tamoxifen. (A) Letrozole treatment, Aromatase positive, PR high, n 
= 16; Aromatase positive, PR low, n = 8; Aromatase positive, PR neg., n = 5. (B) Tamoxifen treatment, Aromatase positive, PR 
high, n = 9; Aromatase positive, PR low, n = 11; Aromatase positive, PR neg., n = 9.
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analyzing aromatase expression in relation to COX-2, ER
and PR.
As mentioned previously, COX-2 is an enzyme that regu-
lates the production of prostaglandins, which in turn reg-
ulate the synthesis of aromatase [36,37]. Several studies
have found association between COX-2 expression and
aromatase expression at the transcriptional level
[35,36,48], and at the protein level using IHC [27,49,50],
supporting that COX-2 may be used as a surrogate marker
for aromatase content in tumor tissue [41]. This is in con-
trast to our finding, in which we compared the expression
of COX-2 and aromatase in invasive carcinoma cells
scored by semi-quantitative IHC and found no associa-
tion between the aromatase expression (SIP score) and
COX-2 expression (Allred score). We assume that the lack
of association may be due to the complex regulation of
the aromatase expression and activity, involving both
COX-2 induced prostaglandins, but also many other stim-
ulatory compounds e. g. cyclic-adenosine-monophos-
phate, glucocorticoids, interleukine-6 and tumor necrosis
factor-α [26,51-57].
We found no association between carcinoma aromatase
and PR expression, whereas a strong trend towards associ-
ation between aromatase and ER in the carcinoma cells
was found. This result is supported by Miki et al. who
found no correlation between PR status and aromatase
mRNA expression level in carcinoma cells and a signifi-
cant association between aromatase mRNA and ER status
in carcinoma cells [58]. This would imply that in situ
estrogen production in the carcinoma cells is not the
major source for ER-induced PR expression, an observa-
tion also supported by another recent study [46] in which
aromatase, like ER, was expressed in inherently less
aggressive tumors.
In carcinoma cells neither COX-2 nor aromatase expres-
sion alone were able to select groups of patients with
superior benefit from tamoxifen therapy, but for patients
with aromatase positive tumors a high PR expression
identified a group of patients for whom endocrine treat-
ment resulted in significantly longer TTP (P = 0.023). For
letrozole treatment, patients with aromatase positive
tumor cells and high PR expression had longer progres-
sion free survival (P = 0.059). This was not observed for
patients treated with tamoxifen, indicating that in
advanced disease the superiority of letrozole to tamoxifen
is primarily observed in the group of patients with aro-
matase positive and high PR expression in the primary
tumor cells.
Conclusion
In summary, our results suggest that aromatase is too het-
erogeneously expressed in tumor tissue to allow detection
in TMAs with 2 mm core size. COX-2 expression in breast
carcinoma cells was not found to be a surrogate marker of
aromatase expression, and neither COX-2 nor aromatase
expression in carcinoma cells predicted response to letro-
zole or tamoxifen treatment. The lack of association
between PR and in situ aromatase expression as well as no
predictive value of aromatase expression for response to
endocrine therapy, suggest that the estrogen synthesis in
the carcinoma cells is not the major source for intratu-
moral estrogen. The strong trend towards an association
of in situ carcinoma aromatase expression with ER expres-
sion may point towards aromatase as indicator of a good
prognosis. In advanced disease, carcinoma cell aromatase
expression in combination with high PR expression may
select letrozole treated patients with longer time to pro-
gression.
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